GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadrenal Therapeutics Inc (NAS:CVKD) » Definitions » Price-to-Owner-Earnings

Cadrenal Therapeutics (Cadrenal Therapeutics) Price-to-Owner-Earnings : (As of Jun. 19, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Cadrenal Therapeutics Price-to-Owner-Earnings?

As of today (2024-06-19), Cadrenal Therapeutics's share price is $0.4765. Cadrenal Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Cadrenal Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


CVKD's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.725
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-19), Cadrenal Therapeutics's share price is $0.4765. Cadrenal Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.31. Therefore, Cadrenal Therapeutics's PE Ratio for today is At Loss.

As of today (2024-06-19), Cadrenal Therapeutics's share price is $0.4765. Cadrenal Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.31. Therefore, Cadrenal Therapeutics's PE Ratio without NRI for today is At Loss.


Cadrenal Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Cadrenal Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadrenal Therapeutics Price-to-Owner-Earnings Chart

Cadrenal Therapeutics Annual Data
Trend Dec22 Dec23
Price-to-Owner-Earnings
- -

Cadrenal Therapeutics Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Cadrenal Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Cadrenal Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cadrenal Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cadrenal Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Cadrenal Therapeutics's Price-to-Owner-Earnings falls into.



Cadrenal Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Cadrenal Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.4765/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cadrenal Therapeutics  (NAS:CVKD) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Cadrenal Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Cadrenal Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Cadrenal Therapeutics (Cadrenal Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
822 A1A North, Suite 306, Ponte Vedra, FL, USA, 32082
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
Executives
John Raymond Murphy director 233 S PATTERSON AVE, SPRINGFIELD MO 65802
Quang X Pham director, 10 percent owner, officer: CEO and Chairman 89 MELROSE DRIVE, MISSION VIEJO CA 92692
Robert Lisicki director C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Douglas W Losordo officer: Chief Medical Officer 13 FOX MEADOW RD, SCARSDALE NY 10583
Steven Zelenkofske director 120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920
Matthew K Szot officer: Chief Financial Officer 802 NORTH DOUTY STREET, HANFORD CA 93230
Glynn Wilson director 2483 NE JULEP STREET, ISSAQUAH WA 98029